Drug intelligence / Profile preview

MAB003

Development stage: Preclinical
Lead developer: MabSwitch
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

MAB003 is a preclinical-stage T-cell engager being developed by MabSwitch for the treatment of blood cancers and solid tumors. It is built upon the company's proprietary SaefTE (Switchable Affinity T-cell Engager) platform, which is designed to recruit T cells to tumor cells while allowing for the regulation of T-cell activity. This switchable-affinity mechanism is intended to improve the safety profile of T-cell engagers by providing a means to control activation, potentially mitigating common toxicities such as cytokine release syndrome (CRS).

Other names: SaefTESwitchable Affinity T-cell Engager

Beyond the preview

Go deeper on MAB003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAB003.

Explore the full profile